Search

Despite increasing ability to understand and correct molecular derangements in disease, genomics and novel phenotypic assays are unevenly deployed in clinical practice. This has hampered translational research and our ability to identify clinically actionable subtypes of disease. Historic examples illustrate how the perspectives of stakeholders across the healthcare ecosystem can influence adoption of innovations in healthcare. Consideration of these factors, from discovery to implementation, can accelerate adoption of new molecular and digital phenotypes in a 'learning' healthcare ecosystem. [ABSTRACT FROM AUTHOR]

The article projects the future of cardiovascular genomics and genetics in the U.S. Topics discussed include an overview of cardiovascular genetics, the gap of phenotype in precision medicine, the impact of cardiovascular genomics and genetics on health, and the genetic architecture of cardiovascular system.

The article projects the future of cardiovascular treatment options in the U.S. Topics discussed include the concepts of cardiovascular disease and their association with therapy, the target population of cardiovascular community, various drug discovery approaches and their driving factors, and the emergence of different classes of therapeutics.

An editorial is presented which discusses the state-of-the-art strategies to assess the causality of newly identified variants in potential cardiovascular disease genes. It mentions the discovery of numerous disease genes for cardiomyopathies, arrhythmias, aortopathies, and other disorders through genetic and genomic studies which demontsrate complex relationships between genotype and phenotype.

As the current paradigms of drug discovery evolve, it has become clear that a more comprehensive understanding of the interactions between small molecules and organismal biology will be vital. The zebrafish is emerging as a complement to existing in vitro technologies and established preclinical in vivo models that can be scaled for high-throughput. In this review, we highlight the current status of zebrafish toxicology studies, identify potential future niches for the model in the drug development pipeline, and define the hurdles that must be overcome as zebrafish technologies are refined for systematic toxicology. [ABSTRACT FROM AUTHOR]

The authors reflect on the insights from genome-wide associations (GWAs). Topics include correlation between common variants and peripheral or tissue-specific expression quantitative trait loci (eQTL), a study by N. A. M. Almontashiri and colleagues on disruption of specific transcription factor (TF) binding sites, and a phenotype gap in modern human genetics.

The article reports that patient care and biomedical research will undoubtedly be increasingly influenced by genomic medicine efforts in the coming years. In his 2016 budget proposal, former U.S. President Barack Obama allocated $215 million to fund the Precision Medicine Initiative. Some groups have already taken steps to develop and implement genomics training into various medical education paths.

The article focuses on the projected future of the U.S. cardiovascular biomedicine. Topics discussed include the application of molecular medicine and its mechanistic insights to clinical medicine, the generation of recombinant proteins, and the significance of cardiovascular biomedicine in transformation biomedicine.

The article discusses research concerning the need for quantitative tools in clinical genomic studies to determine the association of genotype to phenotype. An overview on the establishment of initial disease gene in segregation studies of multiple independent families and specific variant in the gene, is provided. Also outlined is the opportunities for genomic medicine and the hurdles with combination of remarkable degradation in pedigree information.

The field of genetics and genomics has advanced considerably with the achievement of recent milestones encompassing the identification of many loci for cardiovascular disease and variable drug responses. Despite this achievement, a gap exists in the understanding and advancement to meaningful translation that directly affects disease prevention and clinical care. The purpose of this scientific statement is to address the gap between genetic discoveries and their practical application to cardiovascular clinical care. In brief, this scientific statement assesses the current timeline for effective translation of basic discoveries to clinical advances, highlighting past successes. Current discoveries in the area of genetics and genomics are covered next, followed by future expectations, tools, and competencies for achieving the goal of improving clinical care. [ABSTRACT FROM AUTHOR]

Genome-wide association (GWA) studies have linked thousands of loci to human diseases, but the causal genes and variants at these loci generally remain unknown. Although investigators typically focus on genes closest to the associated polymorphisms, the causal gene is often more distal. Reliance on published work to prioritize candidates is biased toward well-characterized genes. We describe a 'prix fixe' strategy and software that uses genome-scale shared-function networks to identify sets of mutually functionally related genes spanning multiple GWA loci. Using associations from ∼100 GWA studies covering ten cancer types, our approach outperformed the common alternative strategy in ranking known cancer genes. As more GWA loci are discovered, the strategy will have increased power to elucidate the causes of human disease. [ABSTRACT FROM AUTHOR]